ORTEXORTEX News
Tracking BA? Get live short interest, options flow, and signals on ORTEX.Sign up free →
BA
Earnings PreviewBA

Boeing Back for Another Print, With Analysts Still Pulling Targets Lower

By ORTEX News · Edited by , Editor, ORTEX NewsUpdated 2 min readdata as of 24 Oct 2026, 04:00

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit

BA reports Q3 results on October 27 at $188.35, down about 5% over the past month and still sitting more than $75 below the Street's mean price target, a gap that has narrowed mainly because analysts keep trimming rather than because the stock has recovered.

The target-cut wave that defined the pre-October-21 print has continued even after those results. Morgan Stanley's Kristine Liwag lowered her target to $225 from $250 on October 19, keeping Equal-Weight, making her the most recent move on record. That follows RBC Capital's cut to $235 from $265 the week before. The consensus sits at hold with just four formal hold ratings counted, but the directional drift in price targets is unambiguous: every analyst who has moved in the past six weeks has moved down, with the sole exception of Barclays, which initiated at Overweight with a $300 target on October 9. The stock closed Friday at $188.35, leaving a wide gap to even the most cautious targets, which cuts both ways.

The bull case rests on a $715 billion backlog with more than 6,200 commercial aircraft on order, Q2 revenue up 8% year-over-year to $24.6 billion, and the first positive free cash flow in years at $631 million for Q2 2026. Boeing's EPS surprise factor ranks in the 93rd percentile and its 90-day EPS momentum ranks in the 97th, suggesting the Street has been revising estimates upward in the near term even as longer-term targets compress. The bear case is harder to dismiss: NOPAT over the last twelve months is negative $4.52 billion, return on capital is negative 7.08%, and a P/E of 66x on fragile earnings gives little room for further execution stumbles. Airbus, Lockheed Martin, and Northrop Grumman all compete directly across different segments, and any slip in production rates or supply-chain stability could reopen the profitability wound.

The lending market is irrelevant as a signal here. Availability is enormous at 4,687%, meaning there are roughly 47 shares available to borrow for every one currently lent out. Short interest is just under 2% of the free float and has edged down about 1.6% over the past week and 6.4% over the past month. Cost to borrow is 0.43%, a low rate that has crept up about 13% in a week but from a negligible base. There is no short-squeeze tension, no borrow squeeze, and no sign that bears are pressing this via the lending market. Wikipedia attention toward Boeing is running 1.3 standard deviations above its own 90-day average, pointing to elevated retail interest around the print, though that is a sentiment signal rather than a financial indicator.

Among peers, BA fell about 1% on the week while HII and RTX each added around 4%, and SARO gained 3.5%. GE and CW were the exceptions, each falling roughly 5% to 6%. The previous Q3 print on October 21 produced a single-day move of negative 1.5%, consistent with the muted reactions in earlier 2026 prints. The October 27 release will test whether Boeing can show that Q2's positive free cash flow was a turning point rather than a one-quarter event, and whether production efficiency is improving fast enough to close the gap between a record backlog and still-negative returns on capital.

Stocks in this article

See the live data behind this article on ORTEX.

Open BA on ORTEX →

How this article was generated

Generated
24 Oct 2026, 04:03
Data as of
24 Oct 2026, 04:00
Prompt version
v1.0
Data sources
Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioningORTEX Alpha signalsRecent ORTEX notesAlt DataPrevious Mi Articles

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.